{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:25:50Z","timestamp":1783635950632,"version":"3.55.0"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>We report a case of SMARCA4-deficient poorly-to-undifferentiated gastric carcinoma. The patient underwent surgical resection. Postoperative treatment combined chemotherapy, immunotherapy, and targeted therapy. The regimen included ifosfamide, liposomal doxorubicin hydrochloride, cadonilimab, and anlotinib capsules. Follow-up to date shows no tumor recurrence or metastasis. The postoperative relapse-free survival (RFS) has now reached 33 months. Primary gastric SMARCA4-deficient undifferentiated tumors carry a poor prognosis, with survival typically under one year. Here we present a successfully treated case of this tumor type originating in the stomach. This case may serve as a reference for future management of such tumors.<\/jats:p>","DOI":"10.3389\/fonc.2026.1775517","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T05:19:09Z","timestamp":1771910349000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: A successfully managed case of SMARCA4-deficient undifferentiated gastric carcinoma"],"prefix":"10.3389","volume":"16","author":[{"given":"Rui","family":"Peng","sequence":"first","affiliation":[{"name":"Department of General Surgery, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingping","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3068","article-title":"SWI\/SNF nucleosome remodellers and cancer","volume":"11","author":"Wilson","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0433","article-title":"SMARCA4: implications of an altered chromatin-remodeling gene for cancer development and therapy","volume":"20","author":"Mardinian","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2017.61","article-title":"SMARCA4-deficient thoracic sarcoma: a distinctive clinicopathological entity with undifferentiated rhabdoid morphology and aggressive behavior","volume":"30","author":"Sauter","year":"2017","journal-title":"Mod Pathol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2922","article-title":"Recurrent SMARCA4 mutations in small cell carcinoma of the ovary","volume":"46","author":"Jelinic","year":"2014","journal-title":"Nat Genet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-024-01510-9","article-title":"SMARCA4-deficient undifferentiated gastric carcinoma: a case series and literature review","volume":"27","author":"An","year":"2024","journal-title":"Gastric Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.asjsur.2023.07.078","article-title":"A case report of SMARCA4-deficient undifferentiated tumor in the esophago-gastric junction","volume":"46","author":"Deng","year":"2023","journal-title":"Asian J Surg"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2023.2180794","article-title":"Cadonilimab, a tetravalent PD-1\/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity","volume":"15","author":"Pang","year":"2023","journal-title":"MAbs"},{"key":"B8","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13045-018-0664-7","article-title":"Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development","volume":"11","author":"Shen","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djad085","article-title":"Tazemetostat for tumors harboring SMARCB1\/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C","volume":"115","author":"Chi","year":"2023","journal-title":"J Natl Cancer Inst"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-20-1744","article-title":"BRG1 loss predisposes lung cancers to replicative stress and ATR dependency","volume":"80","author":"Gupta","year":"2020","journal-title":"Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2023.108366","article-title":"Ifosfamide - History, efficacy, toxicity and encephalopathy","volume":"243","author":"Idle","year":"2023","journal-title":"Pharmacol Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0939-x","article-title":"Anlotinib: first global approval","volume":"78","author":"Syed","year":"2018","journal-title":"Drugs"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01761-9","article-title":"Cadonilimab: first approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1186\/s13000-025-01651-0","article-title":"Gastric SMARCA4-deficient undifferentiated tumors: clinicopathological analysis of two cases in a single center","volume":"20","author":"Cheng","year":"2025","journal-title":"Diagn Pathol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12943-025-02305-x","article-title":"Advances in cancer immunotherapy: historical perspectives, current developments, and future directions","volume":"24","author":"Zhang","year":"2025","journal-title":"Mol Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1775517\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T05:19:10Z","timestamp":1771910350000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1775517\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":15,"alternative-id":["10.3389\/fonc.2026.1775517"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1775517","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]},"article-number":"1775517"}}